Conversion to Parkinsonism and Dementia in REM-Sleep Behavior Disorder Using the Chronobiotic Melatonin

Dieter Kunz, MD, Sophia Stotz, MSc, Frederik Bes, PhD

Supplementary Material

Table of Contents	Page Number
1. Methods	
1.1 Procedure history	2
1.2 Patients	2
1.3 Staging of synucleinopathy	3
1.3.1 Neurocognitive testing	3
1.3.2 Neurologic/motoric evaluation	3
1.3.3 Neurovegetative questioning	3
1.3.4 Olfaction testing	4
1.3.5 Dopamine transporter density	4
1.3.6 Phenoconversion	4
1.4 RBD symptom severity Rating Scale – Ikelos-RS	4
1.5 Polysomnography	4
1.6 Statistical methods	5
2. Results	
2.1 Survival analysis	6
Table 1: Results Cox's proportional-hazards model	6
2.2 CERAD-Plus	6
2.2.1 Statistical analysis	6
Table 2: Descriptive statistics "CERAD-Plus"	7
2.2.2 Results model 1	7
Table 3: Results mixed model 1 "CERAD-Plus:Wordlist encoding"	7
Table 4: Results mixed model 1 "CERAD-Plus:Trail Making Test – Part	
2.2.3 Results model 2	9
Table 5: Results mixed model 2 "CERAD-Plus:Wordlist encoding"	9-10
Table 6: Results mixed model 2 "CERAD-Plus:Trail Making Test – Part	
2.3 UPDRS-III	11
2.3.1 Statistical analysis	11
Table 7: Descriptive statistics "UPDRS-III"	11
2.3.2 Results model 1	12
Table 8: Results mixed model 1 "UPDRS-III"	12
2.3.3 Results model 2	13 13-14
Table 9: Results mixed model 2 "UPDRS-III" 2.4 Ikelos-RS/CGI	13-14
2.4.1 Validation	14
2.4.1 Validation 2.4.2 Statistical analysis	14
2.4.3 Results model A	14
Table 10: Results mixed model A "Ikelos-RS"	14-21
2.4.4 Results model B	22
Table 11: Results mixed model B "Ikelos-RS" (I)	22-23
Table 12: Results mixed model B "Ikelos-RS" (II)	24-27
References for Supplement	28
references for supplement	20

1. Methods

1.1 Procedure history

The Clinic for Sleep- & Chronomedicine at St. Hedwig-Hospital in Berlin, Germany, was founded in 2008, with diagnosis and treatment initiation in neurologic/psychiatric sleep disorders as major aim. Patients are referred or initiate contact themselves to our outpatient clinic. Diagnosis is performed in clinical interview (including a battery of psychometric testing), sometimes supported by several weeks of actigraphy. Depending on indication – referring to criteria of the International Classification of Sleep Disorders (ICSD-3; AASM, 2014) – patients may undergo diagnostic video-supported polysomnography (vPSG). After final diagnosis, treatments are initiated or proposed and patients return to their referring physician.

In 1995 we introduced the use of melatonin as a therapy in patients with REM sleep Behavior Disorder (RBD) (Kunz and Bes, 1997). Melatonin showed a gradual response over weeks, sometimes months, but also an outlasting effect after discontinuation of treatment, sometimes over years (Kunz and Bes, 1999; Kunz and Mahlberg, 2010). Since then, we have therefore recommended or initiated melatonin treatment in almost all of our patients with RBD. Those patients who questioned the need to continue long-term melatonin treatment after RBD symptoms had improved, were advised to discontinue after at least six months treatment and to contact again in case of reemergence of symptoms, or on demand.

Patients clinically suspected to have RBD are always advised by us to pass through a three night's vPSG. Prior to the third night, long-term melatonin treatment according to a chronobiotic protocol is initiated. This protocol basically implies one major instruction: to administer melatonin "always at the same clock time" once per day. This clock time should be established at 30 minutes prior to the *habitual* bedtime. In cases where this fixed time cannot be kept, patients are instructed to skip melatonin intake that night.

At the beginning of 2017 we started to reanalyze our records in order to evaluate systematically the course of treatment response in our patients, as well as confounding factors and response rates to melatonin. During this evaluation we observed that the rate of phenoconversion to clinical synucleinopathy in our patients treated with melatonin was much lower than what was usually reported in the literature for patients with similar characteristics. Thus, starting October 2018, we contacted all of our RBD patients for the evaluation of phenoconversion to clinical synucleinopathy. For treatment response we specifically developed a RBD-rating scale called Ikelos-RS, which we validated with Clinical Global Impression – CGI (Guy, 1976).

1.2 Patients

Until August 2020 a total of 282 consecutive patients initially had been diagnosed with RBD. Thirty-nine patients had already converted to Lewy body dementia (LBD; n=19) or Morbus Parkinson (n=20) at the time of diagnostic PSG or first melatonin intake. None of our patients had developed Multiple System Atrophy (MSA). Twenty-five patients were diagnosed with secondary RBD: 23 were suffering from sleep apnea with RSWA and out-acting behavior occurring during breathing abnormalities only; 2 had developed RBD after antidepressant treatment, which resolved clinically completely after medication had stopped. Twelve patients – diagnosed since January 2020 – did not yet have a follow-up visit including neurocognitive testing and neurologic/motor evaluation after at least six months of melatonin treatment. None of these 37 RBD patients (25 secondary recontacted in 2020 and 12 new) had developed clinical synucleinopathy.

Finally, 206 patients were diagnosed with isolated RBD (iRBD) due to clinical interview and vPSG according to ICSD-3 criteria and included in our observational study. Five patients within this group were considered as with provisional RBD. They reported clear clinical RBD behavior, clinical evaluation showed absence of any other possible causal disorder/medication, and vPSG showed RSWA, but no complex behavior during REM sleep in video recordings.

Thirty-nine of 206 iRBD patients chose not to be treated with melatonin over at least six months. Reasons were: a) patients experienced an initial worsening or treatment failure (melatonin stopped after 1-7 nights; n=16); b) patients were hesitant to take melatonin or their treating physicians were reluctant to prescribe it (melatonin was stopped within 4 weeks; n=10); c) patients discontinued because melatonin showed good effects and discontinuation after up to 3 months did not result in reoccurrence of RBD-symptoms: patients "felt no need in continuing treatment" (n=13). In those 26 patients feeling not sufficiently treated with melatonin, the usual mixture of therapies was applied by their neurologist or general practitioner (e.g. clonazepam, other benzodiazepines, zolpidem, dopaminergic agents, mirtazapine, trazodone).

Of these 39 patients, 35 could directly be re-contacted in 2019/2020 for follow-up. Three patients had died but referring physician reported premortal physical/mental status, one patient could not be reached in person and other sources of information were not available. Consequently, the last available follow-up was included in our observation. 10/39 patients received beta blockers (Metoprolol (n=5) and Bisoprolol (n=5)) at baseline. 12 patients took one or more of the following antidepressant medication: Duloxetin (n=3), Venlafaxin (n=2), Sertralin (n=2), Agomelatine (n=1), Doxepin (n=1), Citalopram (n=1), Escitalopram (n=1), Mirtazapin (n=1), Opipramol (n=1), Paroxetin (n=1) and Trazodon (n=1).

The remaining 167 iRBD patients were long-term treated with melatonin, i.e. for at least six months, according to a chronobiotic protocol: they received a slow-release form 2mg/day, always at the same, individually determined clock time. Twenty-one patients temporarily increased melatonin doses to 4 and 8mg without any effect and returned to 2mg. In the light of a possible neuroprotective effect by melatonin in RBD, 10 of 30 patients who discontinued melatonin treatment after six months restarted melatonin treatment after re-contact in 2018. In none of these 30 patients RBD symptoms had worsened during melatonin-free period. Of the 167 patients, 147 could directly be recontacted in 2020 for regular follow-up. 11 could not be reached in person. In these cases, spouses and referring physicians were contacted and asked if the patients had recently shown signs of parkinsonism or dementia. Eight patients had died and the referring physician could report premortal physical / mental status. In 1 patient information was unavailable (family had moved to an unknown place of residence in 2017; the last available follow-up, five years after diagnosis/treatment initiation, was therefore used in our observation). 55/167 patients received beta blockers (Metoprolol (n=25), Bisoprolol (n=23), Nebivolol (n=5), Solatol (n=1), unknown (n=1)) at baseline. 30 patients took one ore more of the following antidepressant medication: Citalopram (n=7), Escitalopram (n=5), Venlafaxin (n=5), Duloxetin (n=3), Mirtazapin (n=3), Trimipramin (n=3), Amitriptylin (n=2), Clomipramin (n=2), Paroxetin (n=2), Agomelatine (n=1), Bupropion (n=1), Doxepin (n=1), Nortrilen (n=1) and Opipramol (n=1).

1.3 Staging of synucleinopathy

Starting by the end of 2015, all of our iRBD patients were offered a staging of prodromal state in the synucleinopathy process. The test-battery consisted of neurocognitive testing, neurologic/ motoric evaluation of Parkinson severity, neurovegetative questioning, olfaction testing, as well as dopamine transporter single-photon emission computed tomography (DaT-SPECT). CERAD-Plus and UPDRS-III were repeated annually since.

1.3.1 Neurocognitive testing

The extended German version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-Plus, Schmid *et al.*, 2014) consisting of 11 different subtests, was used to measure cognitive performance on the domains language, memory, attention/praxis and orientation. Data entered by the patient are converted into z-values, based on a comparison with the standard population (CERAD: N=1100; age 49-92 years; Plus: N=604; age 55-88 years, Schmid *et al.*, 2014), taking into account gender, age and years of education. The CERAD-Plus was performed in 141 at least once after six months of melatonin treatment, with an average follow up of 3.4±2.9 years. Ninety-one patients were without melatonin treatment at initial examination. Fifty patients had started melatonin treatment prior to the initial CERAD-Plus-examination, implying that for them no CERAD-Plus was available at baseline.

1.3.2 Neurologic/motoric evaluation

Presence of motor signs was assessed using the Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) part III (Goetz *et al.*, 2008). In the present study, 153 patients were tested within the UPDRS-III at least once after at least six months of melatonin treatment with an average follow up of 3.5 ± 2.9 years. Seventy-five patients were without melatonin treatment at initial examination. Seventy-eight patients had started melatonin treatment before the initial examination, implying that for them no UPDRS-III was available at baseline.

1.3.3 Neurovegetative questioning

Autonomic dysfunction was evaluated since 2018 in 38 patients without melatonin at baseline examination using the Scales for Outcomes in Parkinson's disease-Autonomic (SCOPA-AUT, Visser *et al.*, 2004), assessing gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor and sexual symptoms.

1.3.4 Olfaction testing

Olfactory abilities were measured once in 130 patients via Sniffin' Sticks Extended Test (Hummel *et al.*, 1997), of which 96 patients did not receive melatonin at baseline. The results of three subtests (threshold, discrimination and identification test) were added up to a total score, which was classified as \leq 15.5: anosmia, \leq 31: hyposmia and \geq 31: normosmia.

1.3.5 Dopamine transporter density

Patients underwent DaT-SPECT after intravenous injection of 130 MBq ¹²³I-FP-CIT, in order to evaluate reduced presynaptic dopamine transporter binding. Striatal-to-occipital cortex uptake ratios and z-scores (judged to be reduced when more than 2 SD) were calculated for caudate nucleus and anterior and posterior putamen. The interpretation of FP-CIT SPECT was based on visual assessment of the reconstructed SPECT images by a nuclear medicine expert. Visual reading was supported by semiquantitative BRASS-analysis. Based on both statistical and visual analysis scans were evaluated as "inconspicuous" (clear, left-right symmetric delineation of both striata), "pathologic" (distinct uniform or asymmetric reduction) or "borderline" with respect to the presence of Parkinson's disease (Zubal *et al.*, 2007; Djang *et al.*, 2012). In total, 117 out of 167 patients underwent DaT-SPECT, from which 77 without melatonin at baseline conditions.

1.3.6 Phenoconversion

In the cohort of patients being long-term treated with melatonin, phenoconversion to Morbus Parkinson, LBD or MSA was diagnosed on the basis of clinical neurological evaluation performed by our site. Decision was supported by CERAD-Plus and UPDRS-III. In those patients unable to be reevaluated at our site – due to death prior to recontact in 2018/2019/2020 (n=8), or not being interested in specific evaluation when contacted in 2019/2020 (n=11) – diagnosis of phenoconversion was decided on the basis of the referring neurologist's evaluation. Almost all of the patients (91%) were under supervision of a referring neurologist. In remaining 1 patient we were unable to identify current address or physician. There, last follow-up available was included. Neurologists were not advised as to early or late start of specific antiparkinsonian / antidementia treatment. Whenever neurologists initiated such treatment this was considered as due to phenoconversion.

Neurocognitive Disorder (NCD) was defined according to the DSM-5 criteria (APA, 2015), i.a. subjective complaint about cognitive abilities and objective cognitive impairments (at least 2 subtests in CERAD-Plus with a z-score below -1.3; Aebi *et al.*, 2002). Out of 141 patients who were tested within the CERAD-Plus at least once after 6 months of melatonin treatment, 16 patients fulfilled the criteria for NCD at baseline examination.

1.4 RBD symptom severity Rating Scale – Ikelos-RS

RBD symptom severity was rated by a clinician based on interview with patient's bed partner only (mostly personal or by phone-call; when symptom severity was unchanged, patients report of bedpartner's observation was accepted). Observational periods were either the last 6 months (default), or since the last interview if less than 6 months. In case a bed-partner did not exist (n=8), short-term observations by friends or families during visits or joined vacations were taken with shorter observational periods. The Ikelos-RS was filled out at baseline (approximately at the time of vPSG) and at every follow-up. Severity of RBD symptoms was evaluated on two dimensions: On the first scale "frequency" (running from 0 to 4), the occurrence of symptoms is estimated from never (=0), to ≤2-3 times a month (=1), 1-2 times a week (=2), 3-5 times a week (=3) and daily (=4). The second scale "expression" (running from 0 to 3), describes the form of the most severe manifestation of RBD symptoms from speech or slight distal movements (=0) to screaming or complex, non-aggressive movements (=1), complex movements with risk of injury (=2) and leaving the bed (=3). Both ratings are added to a total score (range 0-7) and are supplemented by two components of the Clinical Global Impression (CGI-Severity Scale, CGI-S, and CGI-Improvement Scale, CGI-I; Guy, 1976). Validation was performed with regard to convergent validity, interrater- and test-retest reliability (see lower section 2.4.1).

1.5 Polysomnography

All patients underwent full night video-supported polysomnography (vPSG) on three consecutive nights. The first night was intended for adaptation to the laboratory conditions and the following two nights for diagnostic purposes. In case of RBD diagnosis, long-term treatment with melatonin was started on the third night.

PSG was performed with digital recording systems (predominantly Monet 24-CPU, TMS International, Enschede, The Netherlands or Sagura Polysomnograph 2000, Mühlheim, Germany, with Rembrandt version 7.5 software, Medcare Automation, Amsterdam, The Netherlands). It included electro-encephalographic (EEG)

monitoring (sample rate 160 Hz, high-pass filter 0.3 Hz, low-pass 70 Hz) with the following 10-20-system based derivations: frontal region (F3, F4), central region (C3, C4) and occipital region (O1, O2), each referred to the contra-lateral mastoid (A1, A2). In addition, further continuous measurements were performed: Electro-oculography (sample rate 200 Hz, filter settings 0.3-70 Hz), bipolar surface EMG of m. mentalis and mm. tibiales anterior (sample rate 200 Hz, filter settings 10-120 Hz), electrocardiography (ECG), deep body temperature (rectal thermistor), respiratory flow (nasal-oral thermistor or nasal pressure sensor), respiratory effort of chest and abdomen (induction-plethysmography) and oxyhemoglobine saturation measured at the index finger. Snoring sounds were detected by either a microphone attached to the skin of the throat or derived from a bandpass (30-70 Hz) filtered air flow pressure signal. A video (infra-red, 25 fps resolution) and audio recording (PCM, 8 kHz, 8 bit, mono) was performed synchronously with all PSG measurements. Bio-calibration was performed prior to the start of each recording to ensure adequate signal quality. Each recording took place in a dark, low-noise single-bed room.

1.6 Statistical methods

Scores of cognitive and motor examinations in patients from baseline to follow up tests were investigated with linear mixed model analyses. Only measurements of patients with at least one follow up after baseline were included and allocated to three different, consecutive time categories with comparable group sizes.

In model 1 it was tested whether changes in cognitive or motor scores could be detected over time. Within model 2 it was investigated whether performance in follow up examinations was dependent on the baseline level of cognitive or motor performance, testing the hypothesis that treatment with melatonin results in a normalization of eventual impairments, i.e. with clinically most impaired patients profiting most from treatment.

The validation of the Ikelos-RS within the present publication included evaluation of convergent validity within a bivariate correlation analysis (Spearman's rho) with Ikelos-RS and CGI-S. Spearman's rank correlation coefficient was also used to measure test-retest and interrater reliability. Further validation using i.a. videometric data and RSWA are part of the PhD thesis of one of the authors (SS) and will be reported elsewhere.

The Ikelos-RS total score is, strictly speaking, an ordinal measure. However, to allow robust statistical modelling and because higher Ikelos-RS-values are associated with more pronounced symptoms, a linear mixed model was preferred over a cumulative link mixed model for ordinal data to test time and group effects. In previous studies, it was shown that analyzing ordinally scaled data with parametric methods did not result in high type I error rates (Norman, 2010). Therefore, changes in RBD symptom severity and differences over time between different groups, categorized regarding therapy, confounding co-medication, inadequate timing or continuity of melatonin intake, were investigated within a random intercept model.

Bonferroni post-hoc test was used for multiple testing correction in all executed mixed models.

Within each model, p values less than 0.05 were evaluated to be significant. All statistical analyses were performed in IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY).

2. Results

2.1 Survival analysis

Log-rank test indicated a significant difference between the survival curves of patients with chronobiotic protocol (n=167) vs. mixed treatment (n=39) with melatonin (χ^2 =35.43, p<0.001).

Cox's proportional-hazards model was applied using group classification (chronobiotic protocol vs. mixed treatment) as an explanatory variable. Results indicate that there is strong evidence that group classification is associated with the length of survival, showing that being treated with melatonin reduces the hazard by a factor of 0.07.

Table 1: Results Cox's proportional-hazards model

							95 % CI fo	or Exp(B)
	В	SE	Wald	df	Sig.	Exp(B)	Lower Bound	Upper Bound
GROUP	-2.696	.597	20.377	1	.000	.067	.021	.217

2.2 CERAD-Plus

2.2.1 Statistical analysis

2.2.1.1 Implementation

The CERAD-Plus was performed at least once after six months of melatonin treatment with an average follow up of 3.4 ± 2.9 years (range: 0.5-21.7yrs) in 141/167 iRBD patients. For further analyses, only those who were untreated at baseline and examined cognitively multiple times (n=91) were included, with 160 follow-up examinations compared at three different time points (=TIMECATEGORY) to cognitive performances at baseline.

2.2.1.2 Model specification

In model 1, analyses were executed for each subtest of the CERAD-Plus (using z-scores) as a dependent variable, treating TIMECATEGORY as a fixed, patient ID (=ID) as a random factor and continuity of melatonin intake (=MEL; "continuously" vs. "discontinuously") as well as DaTSPECT results (=DaT; "normal" vs. "borderline" vs. "pathological" scan) as covariates.

Within model 2, a group factor (=COGNITIONGROUP) was added as a fixed factor for the statistically significant tests from model 1 ("Wordlist encoding" and "Trail Making Test – part A"). Depending on the cognitive performance shown at baseline, patients were categorized into a group of "low", "medium" or "high" performer for each test separately. Additionally, the interaction term of TIMECATEGORY *COGNITIONGROUP was included as a fixed factor besides the variables defined in model 1.

2.2.1.3 Descriptive statistics

Means and standard deviations with ranges in years of the follow up duration for the total and sub-cohort as well as the definition of TIMECATEGORIES, the number of re-tests and mean z-scores with ranges of the different COGNITIONGROUPS are characterized as follows:

Table 2: Descriptive statistics "CERAD-Plus"

	Follow-up durations and re-examinations			Linear mixed model				
Follow up	*		COC	GNITIONGROUP				
(yrs)	(yrs)	re-tests	(yrs)	(yrs)	(yrs)	low	medium	high
				Substest	: "Wordlist encod	ing"		
3.4 ± 2.9 (0.5-21.7)	2.1 ± 1.2 (0.5-4.6)	1x = 45 $2x = 25$ $3x = 19$	0.9		3.1 (1.9-4.6)	-1.2 (-2.50.4) n=30	0.0 (-0.4-0.6) n=31	1.3 (0.6-2.7) n=30
n=141/167	n= 91/167	4x = 2	n= 53	n= 53	n= 54	Su	btest: "TMT-A"	
	n= 160			-1.1 (-3.00.3) n=29	0.1 (-0.3-0.6) n=30	1.4 (0.6-2.9) n=29		

2.2.2 Results model 1 (CERAD-Plus)

Table 3: Results mixed model 1 "CERAD-Plus: Wordlist encoding"

Tests of Fixed Effects								
Source	Num. df	Den. df	F	Sig.				
Intercept	1	69.682	.003	.956				
TIMECATEGORY	3	133.748	7.330	.000				
MEL	1	75.339	2.098	.152				
DaT	1	69.673	3.751	.057				

Estimates									
95% CI									
TIME- CATEGORY	Mean	Std. Error	df	Lower Bound	Upper Bound				
Baseline	.167	.125	102.988	081	.415				
1	.564	.141	140.949	.285	.843				
2	.528	.146	150.549	.240	.817				
3	.677	.153	160.049	.375	.978				

			Pairwise Comp	arisons			
(A)	(J)	Mean				95%	6 CI
(I) TIME- CATEGORY	TIME- CATEGORY	Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
	1	397*	.120	129.018	.007	717	077
Baseline	2	361*	.125	131.437	.027	697	026
	3	510*	.133	135.047	.001	866	154
	Baseline	.397*	.120	129.018	.007	.077	.717
1	2	.036	.147	137.968	1.000	359	.430
	3	113	.151	139.087	1.000	517	.292
	Baseline	.361*	.125	131.437	.027	.026	.697
2	1	036	.147	137.968	1.000	430	.359
	3	148	.153	137.141	1.000	559	.263
	Baseline	.510*	.133	135.047	.001	.154	.866
3	1	.113	.151	139.087	1.000	292	.517
	2	.148	.153	137.141	1.000	263	.559

Table 4: Results mixed model 1 "CERAD-Plus: Trail Making Test – Part A"

Tests of Fixed Effects									
Source	Num. df	Den. df	F	Sig.					
Intercept	1	67.279	4.929	.030					
TIMECATEGORY	3	130.461	5.024	.003					
MEL	1	73.664	.966	.329					
DaT	1	67.193	.665	.418					

Estimates									
				95%	i CI				
TIME- CATEGORY	Mean	Std. Error	df	Lower Bound	Upper Bound				
Baseline	.142	.146	104.948	148	.432				
1	.591	.169	147.888	.257	.925				
2	.619	.172	151.083	.280	.959				
3	.492	.181	160.936	.135	.850				

			Pairwise Compari	isons			
(D)	(1)	Maria				95% CI	
(I) TIME- CATEGORY	(J) TIME- CATEGORY	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
	1	449*	.151	125.586	.021	853	044
Baseline	2	477*	.154	127.476	.014	889	065
	3	350	.164	131.750	.209	790	.090
	Baseline	.449*	.151	125.586	.021	.044	.853
1	2	029	.183	134.845	1.000	518	.460
	3	.099	.189	136.900	1.000	408	.605
	Baseline	.477*	.154	127.476	.014	.065	.889
2	1	.029	.183	134.845	1.000	460	.518
	3	.127	.188	134.457	1.000	377	.632
	Baseline	.350	.164	131.750	.209	090	.790
3	1	099	.189	136.900	1.000	605	.408
	2	127	.188	134.457	1.000	632	.377

2.2.3 Results model 2 (CERAD-Plus)

Table 5: Results mixed model 2 "CERAD-Plus: Wordlist encoding"

Tests of Fixed Effects								
Source Num. df Den. Df F Sig.								
Intercept	1	68.260	.371	.544				
TIMECATEGORY	3	140.448	9.558	.000				
MEL	1	83.506	.039	.844				
DaT	1	68.629	5.578	.021				
COGNITIONGROUP	2	68.743	48.417	.000				
TIMECATEGORY*COGNITIONGROUP	6	140.042	4.936	.000				

	Estin	mates (COGNITION	GROUP*TIMECATEO	GORY)			
					95 % CI		
COGNITIONGROUP	TIMECATEGORY	Mean	Std. Error	df	Lower Bound	Upper Bound	
	Baseline	-1.145	.162	138.223	-1.465	825	
low	1	156	.207	177.647	565	.253	
	2	060	.201	173.918	458	.337	
	3	341	.212	170.249	760	.078	
	Baseline	.046	.139	138.417	229	.321	
P	1	.385	.153	159.896	.083	.687	
medium	2	.252	.178	178.399	099	.602	
	3	.814	.169	165.084	.481	1.147	
	Baseline	1.372	.146	136.912	1.083	1.662	
L:_L	1	1.369	.189	178.513	.996	1.742	
high	2	1.418	.187	174.071	1.049	1.788	
	3	1.221	.227	184.677	.774	1.668	

	Pa	irwise Comparison	s (COGNITIONG	ROUP*TIMECA	ATEGORY)			
			Mean				95%	6 CI
	(I) TIME-	(J)TIME-	Difference				Lower	Upper
COGNITIONGROUP	CATEGORY	CATEGORY	(I-J)	Std. Error	df	Sig. .000	Bound -1.572	Bound
		1	989*	.217	133.703			407
	Baseline	2	-1.085*	.212	133.835	.000	-1.654	516
		3	804*	.223	147.917	.003	-1.402	207
		Baseline	.989*	.217	133.703	.000	.407	1.572
	1	2	095	.257	152.540	1.000	781	.591
low		3	.185	.271	164.326	1.000	538	.909
1011		Baseline	1.085*	.212	133.835	.000	.516	1.654
	2	1	.095	.257	152.540	1.000	591	.781
		3	.281	.248	145.077	1.000	384	.945
		Baseline	.804*	.223	147.917	.003	.207	1.402
	3	1	185	.271	164.326	1.000	909	.538
		2	281	.248	145.077	1.000	945	.384
		1	339	.164	123.783	.243	779	.100
	Baseline	2	206	.187	132.283	1.000	707	.295
		3	768*	.179	139.158	.000	-1.247	289
		Baseline	.339	.164	123.783	.243	100	.779
	1	2	.133	.202	141.299	1.000	407	.674
1.		3	429*	.191	141.718	.157	939	.082
medium		Baseline	.206	.187	132.283	1.000	295	.707
	2	1	133	.202	141.299	1.000	674	.407
		3	562	.210	142.300	.050	-1.124	.000
		Baseline	.768*	.179	139.158	.000	.289	1.247
	3	1	.429	.191	141.718	.157	082	.939
		2	.562	.210	142.300	.050	.000	1.124
		1	.003	.200	133.424	1.000	531	.538
	Baseline	2	046	.193	137.351	1.000	563	.471
1:1		3	.152	.236	144.385	1.000	478	.782
high		Baseline	003	.200	133.424	1.000	538	.531
	1	2	049	.239	152.928	1.000	689	.590
		3	.148	.267	152.724	1.000	566	.863

	Baseline	.046	.193	137.351	1.000	471	.563
2	1	.049	.239	152.928	1.000	590	.689
	3	.198	.270	156.706	1.000	524	.919
	Baseline	152	.236	144.385	1.000	782	.478
3	1	148	.267	152.724	1.000	863	.566
	2	198	.270	156.706	1.000	919	.524

Table 6: Results mixed model 2 "CERAD-Plus: Trail Making Test – Part A"

	Tes	ts of Fixed Effects		
Source	Num. df	Den. df	F	Sig.
Intercept	1	70.374	9.833	.003
TIMECATEGORY	3	135.552	6.450	.000
MEL	1	82.731	.002	.966
DaT	1	70.826	1.417	.238
COGNITIONGROUP	2	70.665	29.687	.000
TIMECATEGORY*COGNITIONGROUP	6	135.143	4.185	.001

	Estimate	es (COGNITIONGROU	P*TIMECATEGO	RY)			
					95 % CI		
COGNITIONGROUP	TIMECATEGORY	Mean	Std. Error	df	Lower Bound	Upper Bound	
	Baseline	-1.246	.196	131.667	-1.633	858	
low	1	436	.227	160.706	884	.011	
	2	127	.261	174.520	641	.387	
	3	224	.261	171.192	739	.291	
	Baseline	.171	.192	131.015	209	.552	
medium	1	.171 .192 1 .778 .247 1	172.826	.291	1.265		
meaium	2	.886	.223	157.268	.445	1.327	
	3	.430	.222	151.411	009	.868	
	Baseline	1.354	.187	129.710	.985	1.724	
L:_L	1	1.371	.225	164.941	.928	1.814	
high	2	.992	.238	171.210	.523	1.461	
	3	1.238	.288	178.590	.669	1.806	

	Pai	rwise Comparisons	(COGNITIONGF	ROUP*TIMECA	TEGORY)			
			Mean				95%	6 CI
COGNITIONGROUP	(I) TIME- CATEGORY	(J) TIME- CATEGORY	Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
		1	809*	.235	125.689	.005	-1.440	179
	Baseline	2	-1.119*	.268	132.683	.000	-1.838	400
		3	-1.022*	.268	138.780	.001	-1.740	303
		Baseline	.809*	.235	125.689	.005	.179	1.440
	1	2	310	.293	137.130	1.000	-1.095	.476
1		3	212	.301	148.128	1.000	-1.017	.592
low		Baseline	1.119*	.268	132.683	.000	.400	1.838
	2	1	.310	.293	137.130	1.000	476	1.095
		3	.097	.324	146.374	1.000	768	.963
		Baseline	1.022*	.268	138.780	.001	.303	1.740
	3	1	.212	.301	148.128	1.000	592	1.017
		2	097	.324	146.374	1.000	963	.768
		1	607	.255	129.343	.112	-1.289	.076
	Baseline	2	715*	.230	129.493	.014	-1.331	099
		3	258	.230	133.890	1.000	874	.358
		Baseline	.607	.255	129.343	.112	076	1.289
	1	2	108	.291	145.624	1.000	887	.671
medium		3	.349	.284	144.304	1.000	411	1.108
medium		Baseline	.715*	.230	129.493	.014	.099	1.331
	2	1	.108	.291	145.624	1.000	671	.887
		3	.457	.254	137.054	.450	225	1.138
	3	Baseline	.258	.230	133.890	1.000	358	.874
		1	349	.284	144.304	1.000	-1.108	.411
		2	457	.254	137.054	.450	-1.138	.225
high	Baseline	1	016	.233	127.575	1.000	641	.608

	2	.362	.239	129.167	.794	279	1.003
	3	.117	.295	140.704	1.000	672	.906
	Baseline	.016	.233	127.575	1.000	608	.641
1	2	.379	.282	140.462	1.000	376	1.133
	3	.133	.320	144.146	1.000	723	.990
	Baseline	362	.239	129.167	.794	-1.003	.279
2	1	379	.282	140.462	1.000	-1.133	.376
	3	245	.333	145.510	1.000	-1.137	.646
	Baseline	117	.295	140.704	1.000	906	.672
3	1	133	.320	144.146	1.000	990	.723
	2	.245	.333	145.510	1.000	646	1.137

2.3 UPDRS-III

2.3.1 Statistical analysis

2.3.1.1 Implementation

The UPDRS-III was performed at least once after six months of melatonin treatment with an average follow up of 3.5 ± 2.9 years (range: 0.6-21.7 yrs) in 153/167 iRBD patients. For further analyses, only those patients who were untreated at baseline and examined motorically multiple times (n=75) were included, with 140 follow-up examinations compared at three different time points (=TIMECATEGORY) to motor performance at baseline.

2.3.1.2 Model specification

In model 1, analyses were performed for the UPDRS-III total score as a dependent variable, treating TIMECATEGORY as a fixed, patient ID (=ID) as a random factor and continuity of melatonin intake (=MEL; "continuously" vs. "discontinuously") as well as DaTSPECT results (=DaT; "normal" vs. "borderline" vs. "pathological" scan) as covariates.

Within model 2, a group factor (MOTORGROUP) was added, categorizing patients into "low", "medium" or "high" performer depending on their motor performance at baseline ("high" performer representing the clinically most impaired patients). Also, the interaction term of TIMECATEGORY*MOTORGROUP was included as an additional fixed factor besides the variables defined in model 1.

2.3.1.3 Descriptive statistics

Means and standard deviations with ranges in years of the follow up duration for the total and sub-cohort as well as the definition of TIMECATEGORIES, the number of re-tests and mean z-scores with ranges of the different MOTORGROUPS are characterized as follows:

Table 7: Descriptive statistics "UPDRS-III"

Follow-uj	duration and re-ex	aminations	Linear mixed model						
						N	/OTORGRO	OUP	
Follow up of total cohort (yrs)	Follow up of included sub-cohort (yrs)	Number of re-tests	TIME C. 1 (yrs)	TIME C. 2 (yrs)	TIME C. 3 (yrs)	low	medium	high	
3.5 ± 2.9 (0.6-21.7) n= 153/167	2.3 ± 1.5 (0.5-9.3) n=75/167	1x =28 2x = 31 3x = 14 4x = 2 n= 140	0.9 (0.5-1.1) n= 46	1.7 (1.2-2.3) n= 47	3.5 (2.4-9.3) n= 47	0 (0-0) n=30	1.5 (0.5-2) n=22	5.9 (3-20) n=23	

2.3.2 Results model 1 (UPDRS-III)

Table 8: Results mixed model 1 "UPDRS-III"

Tests o	f Fixed Eff	fects		
C	Num.	Den.	F	g:_
Source	df		-	Sig.
Intercept	1	51.729	2.838	.098
TIMECATEGORY	3	104.045	9.806	.000
MEL	1	51.395	.058	.811
DaT	1	54.562	.332	.567

	E	stimates				
				95% CI		
TIME-	Maria	Std.	16	Lower Bound	Upper Bound	
CATEGORY Baseline	Mean 2.016	Error .376	df 66.361	1.264	2.767	
1	1.148	.403	83.705	.346	1.951	
2	.866	.408	86.896	.055	1.677	
3	.667	.427	97.817	181	1.515	

		I	Pairwise Comparis	sons			
(I)	(J)	Mean				95%	6 CI
TIME- CATEGORY	TIME- CATEGORY	Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
Baseline	1	.868*	.276	102.086	.013	.125	1.610
	2	1.150*	.282	101.899	.001	.391	1.909
	3	1.349*	.309	105.246	.000	.517	2.181
1	Baseline	868*	.276	102.086	.013	-1.610	125
	2	.282	.327	104.758	1.000	597	1.162
	3	.481	.359	107.997	1.000	482	1.445
2	Baseline	-1.150*	.282	101.899	.001	-1.909	391
	1	282	.327	104.758	1.000	-1.162	.597
	3	.199	.351	105.778	1.000	744	1.143
3	Baseline	-1.349*	.309	105.246	.000	-2.181	517
	1	481	.359	107.997	1.000	-1.445	.482
	2	199	.351	105.778	1.000	-1.143	.744

2.3.3 Results model 2 (UPDRS-III)

Table 9: Results mixed model 2 "UPDRS-III"

	Tests of Fixed E	ffects		
Source	Num. df	Den. Df	F	Sig.
Intercept	1	51.122	8.396	.006
TIMECATEGORY	3	103.881	28.067	.000
MEL	1	50.905	.153	.697
DaT	1	54.087	.001	.979
MOTORGROUP	2	51.436	17.146	.000
TIMECATEGORY*MOTORGROUP	6	103.675	13.327	.000

		Estimates (MOTOF	RGROUP*TIMECATE	GORY)		
MOTOR-		•			95 %	6 CI
GROUP	TIME- CATEGORY	Mean	Std. Error	df	Lower Bound	Upper Bound
	Baseline	033	.430	65.446	892	.826
1	1	.066	.457	80.371	843	.975
low	2	010	.472	88.970	948	.928
	3	.169	.517	111.980	855	1.193
	Baseline	1.569	.484	65.506	.602	2.536
medium	1	.692	.518	82.291	339	1.724
meaium	2	.454	.507	77.039	556	1.464
	3	.465	.531	87.903	591	1.521
	Baseline	6.571	.579	66.333	5.415	7.728
1.1.1	1	3.914	.639	91.114	2.645	5.182
high	2	2.889	.659	99.660	1.581	4.197
,	3	2.334	.642	90.887	1.059	3.610

		Pairwise Comp	parisons (TIMECA	TEGORY*MO	TORGROUP)			
			Mean				95%	6 CI
MOTOR-	(I) TIME-	(J) TIME-	Difference				Lower	Upper
GROUP	CATEGORY	CATEGORY	(I-J)	Std. Error	df	Sig.	Bound	Bound
		1	099	.311	101.164	1.000	936	.738
	Baseline	2	023	.329	102.000	1.000	908	.862
		3	202	.392	105.009	1.000	-1.256	.852
		Baseline	.099	.311	101.164	1.000	738	.936
	1	2	.076	.375	104.199	1.000	933	1.085
low		3	103	.438	107.599	1.000	-1.280	1.074
low		Baseline	.023	.329	102.000	1.000	862	.908
	2	1	076	.375	104.199	1.000	-1.085	.933
3		3	179	.451	106.941	1.000	-1.391	1.033
		Baseline	.202	.392	105.009	1.000	852	1.256
	3	1	.103	.438	107.599	1.000	-1.074	1.280
		2	.179	.451	106.941	1.000	-1.033	1.391
Baselir		1	.877	.351	101.412	.085	068	1.821
	Baseline	2	1.115*	.339	99.842	.008	.202	2.028
		3	1.104*	.372	103.957	.022	.103	2.105
		Baseline	877	.351	101.412	.085	-1.821	.068
	1	2	.238	.392	102.922	1.000	817	1.293
medium		3	.227	.437	107.286	1.000	947	1.402
meaium		Baseline	-1.115*	.339	99.842	.008	-2.028	202
	2	1	238	.392	102.922	1.000	-1.293	.817
		3	011	.406	103.970	1.000	-1.103	1.082
		Baseline	-1.104*	.372	103.957	.022	-2.105	103
	3	1	227	.437	107.286	1.000	-1.402	.947
		2	.011	.406	103.970	1.000	-1.082	1.103
		1	2.658*	.457	102.005	.000	1.429	3.886
	Baseline	2	3.683*	.486	102.440	.000	2.375	4.990
		3	4.237*	.462	105.554	.000	2.995	5.479
		Baseline	-2.658*	.457	102.005	.000	-3.886	-1.429
high	1	2	1.025	.586	107.001	.501	552	2.601
		3	1.579*	.562	108.830	.035	.068	3.090
		Baseline	-3.683*	.486	102.440	.000	-4.990	-2.375
	2	1	-1.025	.586	107.001	.501	-2.601	.552

		3	.554	.550	104.989	1.000	924	2.033
3		Baseline	-4.237*	.462	105.554	.000	-5.479	-2.995
	3	1	-1.579*	.562	108.830	.035	-3.090	068
		2	554	.550	104.989	1.000	-2.033	.924

2.4 Ikelos-RS/CGI

2.4.1 Validation

To test convergent validity, the Ikelos-RS total score was correlated with the CGI-S in 1153 cases. For the evaluation of the interrater reliability, 45 Ikelos-RS were filled out by two independent physicians. 174 Ikelos-RS were filled out again by the same physician after at least six months. Overall, correlation analyses (using Spearman's rho) showed that the Ikelos-RS can be considered as a valid measuring instrument: Results provide evidence for convergent validity (ρ =.9, p<.001), interrater reliability (ρ =.9, p<.001).

2.4.2 Statistical analysis

2.4.2.1 Implementation

RBD symptom severity was evaluated with a total of 1489 Ikelos-RS at the time of diagnosis and each further visit (usually at least three times per year since 2016) after initiation of treatment, with an average follow up of 4.2 ± 3.1 years (range: 0.6-21.7 years) in all 167 patients under longterm chronobiotic treatment and with an average follow up of 3.1 ± 2.1 years (range: 0.3-7.6 years) in 39 patients under mixed treatments.

To investigate the influence of confounding factors on RBD symptom regression within the first 6 months of melatonin treatment, time courses of the following four subgroups in the group under longterm chronobiotic treatment were compared: 1) patients with beta blockers (n=41), 2) with antidepressants (n=18), 3) with inadequate timing (n=25) and 4) without such confounders (n=77). Because no clear subgroup classification could be determined, data of patients who took both beta blockers and antidepressants (n=6) were not included in the analysis of the first 6 months (model A). For the group under mixed treatments two subgroups were compared: 1) patients short term (up to 3 months) treated with melatonin (n=13), and 2) patients treated with other medications (n=26).

To investigate differences in time courses after six months, the patients of the longterm chronobiotic treatment group were re-classified in patients who 1) continued to take melatonin regularly (n=137) and 2) stopped after 6 months at the latest (n=30), thus including all 167 patients (model B, I). Additionally, time courses of these two groups were compared to both sub-classifications of the patients under mixed treatments (model B, II).

2.4.2.2 Model specification

A random intercept model was performed, treating the Ikelos-RS total score as a dependent variable (=IKELOS). Due to a non-symmetrical distribution, the time variable (months since melatonin treatment) was both logarithmized and squared. Subsequently, time (=ln_TIME) and subgroup classification (=GROUP) were defined as fixed and patient as random factors (=ID). Additionally, the interaction term of ln_TIME*GROUP was included.

2.4.3 Results model A (Ikelos-RS)

Table 10: Results mixed model A "Ikelos-RS"

	Tests of Fixed Effects									
Source	Num. df	Den. Df	F	Sig.						
Intercept	1	913.942	3161.420	0.000						
GROUP	5	893.329	5.463	0.000						
ln_TIME	1	1411.655	398.375	0.000						
ln_TIME* ln_TIME	1	1438.178	178.362	0.000						
GROUP* ln_TIME	5	1413.507	12.259	0.000						
GROUP* ln_TIME* ln_TIME	5	1420.760	10.245	0.000						

	Esti	mates of Fixed	Effects				
						95 %	6 CI
Parameter	Estimate	Std. Error	df	t	Sig.	Lower Bound	Upper Bound
Intercept	5.184824	0.132887	833.039	39.017	0.000	4.923992	5.445657
GROUP (reference: no confounder)		1	ı				
GROUP (timing)	1.139871	0.272585	861.276	4.182	0.000	0.604863	1.674880
GROUP (beta blockers)	0.275746	0.227301	836.604	1.213	0.225	-0.170400	0.721892
GROUP (antidepressants)	-0.068688	0.309461	855.274	-0.222	0.824	-0.676079	0.538703
GROUP (short term melatonin)	0.665816	0.373709	967.846	1.782	0.075	-0.067556	1.399189
GROUP (various)	0.951135	0.276533	921.235	3.440	0.001	0.408428	1.493842
ln_TIME	-2.568642	0.124480	1386.165	-20.635	0.000	-2.812832	-2.324452
ln_TIME* ln_TIME	0.408138	0.028640	1429.236	14.251	0.000	0.351958	0.464319
GROUP* In_TIME (reference: no confounder)					1	I	
GROUP (timing) * ln_TIME	0.824670	0.250492	1381.328	3.292	0.001	0.333284	1.316056
GROUP (beta blockers) * ln_TIME	-0.066039	0.206288	1443.941	-0.320	0.749	-0.470695	0.338617
GROUP (antidepressants) * ln_TIME	0.439222	0.297827	1430.603	1.475	0.140	-0.145003	1.023446
GROUP (short term melatonin) * ln_TIME	-0.744790	0.434854	1371.218	-1.713	0.087	-1.597841	0.108260
GROUP (various) * ln_TIME	2.060543	0.310628	1426.684	6.633	0.000	1.451205	2.669880
GROUP* ln_TIME* ln_TIME (reference: no confound	er)				1	I	
GROUP (timing) * ln_TIME* ln_TIME	-0.256591	0.056744	1423.681	-4.522	0.000	-0.367901	-0.145281
GROUP (beta blockers) * ln_TIME* ln_TIME	-0.008078	0.047190	1392.294	-0.171	0.864	-0.100648	0.084493
GROUP (antidepressants) * ln_TIME* ln_TIME	-0.115238	0.065884	1443.924	-1.749	0.080	-0.244476	0.014001
GROUP (short term melatonin) * ln_TIME* ln_TIME	0.323664	0.109873	1408.042	2.946	0.003	0.108131	0.539197
GROUP (various) * ln_TIME* ln_TIME	-0.322552	0.073796	1443.996	-4.371	0.000	-0.467311	-0.177793

		Estimates	(Baseline)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		5.185	0.133	833.039		4.924	5.446
timing		6.325	0.238	870.2	29	5.858	6.792
beta blockers		5.461	0.184	838.4	59	5.099	5.823
antidepressants		5.116	0.279	860.3	65	4.568	5.665
short term melatonir	1	5.851	0.349	988.3	60	5.165	6.536
various		6.136	0.243	948.8	87	5.660	6.612
		Pairwise Compa	risons (Baseli	ne)			•
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.140*	0.273	861.276	0.000	-1.942	-0.338
	beta blockers	-0.276	0.227	836.604	1.000	-0.945	0.393
	antidepressants	0.069	0.309	855.274	1.000	-0.842	0.980
	short term	-0.666	0.374	967.846	1.000	-1.765	0.434
	various	951*	0.277	921.235	0.009	-1.765	-0.137
timing	beta blockers	0.864	0.301	858.204	0.063	-0.022	1.750
	antidepressants	1.209*	0.367	864.501	0.016	0.128	2.289
	short term	0.474	0.423	949.963	1.000	-0.770	1.718
	various	0.189	0.340	909.745	1.000	-0.811	1.189
	no confounder	1.140*	0.273	861.276	0.000	0.338	1.942
beta blockers	timing	-0.864	0.301	858.204	0.063	-1.750	0.022
	antidepressants	0.344	0.335	853.674	1.000	-0.641	1.330

	short term	-0.390	0.395	954.416	1.000	-1.552	0.772
	various	-0.675	0.305	907.354	0.403	-1.572	0.221
	no confounder	0.276	0.227	836.604	1.000	-0.393	0.945
antidepressants	timing	-1.209*	0.367	864.501	0.016	-2.289	-0.128
	beta blockers	-0.344	0.335	853.674	1.000	-1.330	0.641
	short term	-0.735	0.447	937.136	1.000	-2.051	0.582
	various	-1.020	0.370	897.681	0.090	-2.109	0.069
	no confounder	-0.069	0.309	855.274	1.000	-0.980	0.842
short term	timing	-0.474	0.423	949.963	1.000	-1.718	0.770
	beta blockers	0.390	0.395	954.416	1.000	-0.772	1.552
	antidepressants	0.735	0.447	937.136	1.000	-0.582	2.051
	various	-0.285	0.425	975.437	1.000	-1.537	0.966
	no confounder	0.666	0.374	967.846	1.000	-0.434	1.765
various	timing	-0.189	0.340	909.745	1.000	-1.189	0.811
	beta blockers	0.675	0.305	907.354	0.403	-0.221	1.572
	antidepressants	1.020	0.370	897.681	0.090	-0.069	2.109
	short term	0.285	0.425	975.437	1.000	-0.966	1.537
	no confounder	.951*	0.277	921.235	0.009	0.137	1.765

		Estim	ates (2 weeks	i)			
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		4.268	0.110	476.8	73	4.051	4.484
timing		5.684	0.196	500.6	500.616		6.069
beta blockers		4.517	0.153	504.5	10	4.216	4.819
antidepressants		4.349	0.232	497.5	18	3.893	4.805
short term melatoni	n	4.697	0.283	574.90	07	4.140	5.254
various		5.955	0.199	553.49	95	5.564	6.346
		Pairwise Co	mparisons (2	weeks)			
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.416*	0.225	494.770	0.000	-2.079	-0.753
•	beta blockers	-0.249	0.189	494.881	1.000	-0.807	0.308
	antidepressants	-0.082	0.257	493.634	1.000	-0.839	0.676
	short term	-0.430	0.304	560.722	1.000	-1.326	0.467
	various	-1.688*	0.228	534.244	0.000	-2.359	-1.016
timing	beta blockers	1.167*	0.249	502.093	0.000	0.433	1.901
	antidepressants	1.335*	0.304	498.804	0.000	0.439	2.230
	short term	0.987	0.345	549.537	0.065	-0.029	2.002
	various	-0.271	0.279	526.690	1.000	-1.095	0.552
	no confounder	1.416*	0.225	494.770	0.000	0.753	2.079
beta blockers	timing	-1.167*	0.249	502.093	0.000	-1.901	-0.433
	antidepressants	0.168	0.278	499.632	1.000	-0.653	0.989
	short term	-0.180	0.322	557.972	1.000	-1.130	0.770
	various	-1.438*	0.251	534.600	0.000	-2.179	-0.697
	no confounder	0.249	0.189	494.881	1.000	-0.308	0.807
antidepressants	timing	-1.335*	0.304	498.804	0.000	-2.230	-0.439
	beta blockers	-0.168	0.278	499.632	1.000	-0.989	0.653
	short term	-0.348	0.366	542.220	1.000	-1.428	0.732
	various	-1.606*	0.306	520.371	0.000	-2.508	-0.704
	no confounder	0.082	0.257	493.634	1.000	-0.676	0.839
short term	timing	-0.987	0.345	549.537	0.065	-2.002	0.029
	beta blockers	0.180	0.322	557.972	1.000	-0.770	1.130
	antidepressants	0.348	0.366	542.220	1.000	-0.732	1.428

	various	-1.258*	0.346	567.725	0.005	-2.279	-0.237
	no confounder	0.430	0.304	560.722	1.000	-0.467	1.326
various	timing	0.271	0.279	526.690	1.000	-0.552	1.095
	beta blockers	1.438*	0.251	534.600	0.000	0.697	2.179
	antidepressants	1.606*	0.306	520.371	0.000	0.704	2.508
	short term	1.258*	0.346	567.725	0.005	0.237	2.279
	no confounder	1.688*	0.228	534.244	0.000	1.016	2.359

		Estimates	s (4 weeks)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		3.688	0.102	357.1:	51	3.486	3.889
timing		5.255	0.180	365.650		4.901	5.609
beta blockers		3.917	0.142	366.00	08	3.638	4.196
antidepressants		3.856	0.217	374.2	18	3.429	4.283
short term melatonin		4.006	0.271	481.4	74	3.473	4.539
various		5.842	0.192	456.6	78	5.465	6.219
		Pairwise Compa	arisons (4 wee	ks)			
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.567*	0.207	363.546	0.000	-2.179	-0.956
	beta blockers	-0.229	0.175	362.937	1.000	-0.746	0.287
	antidepressants	-0.168	0.240	371.036	1.000	-0.878	0.541
	short term	-0.318	0.290	463.199	1.000	-1.174	0.537
	various	-2.154*	0.217	431.774	0.000	-2.796	-1.512
timing	beta blockers	1.338*	0.229	365.787	0.000	0.661	2.015
	antidepressants	1.399*	0.282	370.699	0.000	0.566	2.233
	short term	1.249*	0.325	441.596	0.002	0.289	2.210
	various	-0.587	0.263	410.794	0.394	-1.363	0.190
	no confounder	1.567*	0.207	363.546	0.000	0.956	2.179
beta blockers	timing	-1.338*	0.229	365.787	0.000	-2.015	-0.661
	antidepressants	0.061	0.259	371.742	1.000	-0.705	0.827
	short term	-0.089	0.306	453.141	1.000	-0.992	0.814
	various	-1.925*	0.239	421.649	0.000	-2.629	-1.221
	no confounder	0.229	0.175	362.937	1.000	-0.287	0.746
antidepressants	timing	-1.399*	0.282	370.699	0.000	-2.233	-0.566
	beta blockers	-0.061	0.259	371.742	1.000	-0.827	0.705
	short term	-0.150	0.347	435.361	1.000	-1.176	0.875
	various	-1.986*	0.290	407.750	0.000	-2.842	-1.130
	no confounder	0.168	0.240	371.036	1.000	-0.541	0.878
short term	timing	-1.249*	0.325	441.596	0.002	-2.210	-0.289
	beta blockers	0.089	0.306	453.141	1.000	-0.814	0.992
	antidepressants	0.150	0.347	435.361	1.000	-0.875	1.176
	various	-1.836*	0.332	473.019	0.000	-2.816	-0.856
	no confounder	0.318	0.290	463.199	1.000	-0.537	1.174
various	timing	0.587	0.263	410.794	0.394	-0.190	1.363
	beta blockers	1.925*	0.239	421.649	0.000	1.221	2.629
	antidepressants	1.986*	0.290	407.750	0.000	1.130	2.842
	short term	1.836*	0.332	473.019	0.000	0.856	2.816
	no confounder	2.154*	0.217	431.774	0.000	1.512	2.796

		Estimates	s (6 weeks)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		3.259	0.100	318.0	05	3.062	3.456
timing		4.922	0.174	316.9	18	4.580	5.265
beta blockers		3.471	0.137	307.9	38	3.201	3.741
antidepressants		3.485	0.214	336.5	38	3.064	3.907
short term melatonin	l .	3.522	0.276	493.3	57	2.980	4.064
various		5.759	0.196	458.8	01	5.373	6.144
		Pairwise Compa	arisons (6 weel	ks)		'	
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.663*	0.201	317.187	0.000	-2.257	-1.069
	beta blockers	-0.212	0.170	311.378	1.000	-0.714	0.290
	antidepressants	-0.226	0.236	333.120	1.000	-0.925	0.473
	short term	-0.263	0.293	467.430	1.000	-1.129	0.603
	various	-2.500*	0.220	423.878	0.000	-3.149	-1.850
timing	beta blockers	1.451*	0.222	313.435	0.000	0.795	2.107
	antidepressants	1.437*	0.276	328.544	0.000	0.620	2.253
	short term	1.400*	0.326	432.261	0.000	0.437	2.363
	various	837*	0.262	387.628	0.023	-1.611	-0.062
	no confounder	1.663*	0.201	317.187	0.000	1.069	2.257
beta blockers	timing	-1.451*	0.222	313.435	0.000	-2.107	-0.795
	antidepressants	-0.014	0.254	327.860	1.000	-0.766	0.738
	short term	-0.051	0.308	446.868	1.000	-0.960	0.859
	various	-2.287*	0.239	400.131	0.000	-2.994	-1.581
	no confounder	0.212	0.170	311.378	1.000	-0.290	0.714
antidepressants	timing	-1.437*	0.276	328.544	0.000	-2.253	-0.620
	beta blockers	0.014	0.254	327.860	1.000	-0.738	0.766
	short term	-0.037	0.349	425.019	1.000	-1.068	0.995
	various	-2.273*	0.290	386.125	0.000	-3.131	-1.416
	no confounder	0.226	0.236	333.120	1.000	-0.473	0.925
short term	timing	-1.400*	0.326	432.261	0.000	-2.363	-0.437
	beta blockers	0.051	0.308	446.868	1.000	-0.859	0.960
	antidepressants	0.037	0.349	425.019	1.000	-0.995	1.068
	various	-2.237*	0.338	481.413	0.000	-3.235	-1.238
	no confounder	0.263	0.293	467.430	1.000	-0.603	1.129
various	timing	.837*	0.262	387.628	0.023	0.062	1.611
	beta blockers	2.287*	0.239	400.131	0.000	1.581	2.994
	antidepressants	2.273*	0.290	386.125	0.000	1.416	3.131
	short term	2.237*	0.338	481.413	0.000	1.238	3.235
	no confounder	2.500*	0.220	423.878	0.000	1.850	3.149

Estimates (8 weeks)									
				95 9	% CI				
GROUP	Mean	Std. Error	df	Lower Bound	Upper Bound				
no confounder	2.955	0.100	309.412	2.758	3.151				
timing	4.675	0.173	302.765	4.335	5.015				
beta blockers	3.153	0.136	285.056	2.885	3.421				
antidepressants	3.218	0.216	330.971	2.794	3.643				
short term melatonin	3.196	0.284	532.103	2.638	3.755				
various	5.700	0.203	487.739	5.302	6.098				
	Pairwise Con	parisons (8 weeks)			I				

						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.720*	0.200	304.409	0.000	-2.310	-1.130
	beta blockers	-0.198	0.169	293.268	1.000	-0.698	0.301
	antidepressants	-0.263	0.238	327.030	1.000	-0.967	0.440
	short term	-0.241	0.301	499.277	1.000	-1.130	0.647
	various	-2.745*	0.226	444.000	0.000	-3.412	-2.079
timing	beta blockers	1.522*	0.220	295.816	0.000	0.871	2.173
	antidepressants	1.457*	0.277	319.547	0.000	0.639	2.274
	short term	1.479*	0.333	452.725	0.000	0.497	2.461
	various	-1.025*	0.266	395.496	0.002	-1.812	-0.239
	no confounder	1.720*	0.200	304.409	0.000	1.130	2.310
beta blockers	timing	-1.522*	0.220	295.816	0.000	-2.173	-0.871
	antidepressants	-0.065	0.255	316.953	1.000	-0.820	0.690
	short term	-0.043	0.315	469.423	1.000	-0.973	0.887
	various	-2.547*	0.244	408.645	0.000	-3.267	-1.826
	no confounder	0.198	0.169	293.268	1.000	-0.301	0.698
antidepressants	timing	-1.457*	0.277	319.547	0.000	-2.274	-0.639
	beta blockers	0.065	0.255	316.953	1.000	-0.690	0.820
	short term	0.022	0.357	443.892	1.000	-1.032	1.076
	various	-2.482*	0.296	394.583	0.000	-3.356	-1.607
	no confounder	0.263	0.238	327.030	1.000	-0.440	0.967
short term	timing	-1.479 [*]	0.333	452.725	0.000	-2.461	-0.497
	beta blockers	0.043	0.315	469.423	1.000	-0.887	0.973
	antidepressants	-0.022	0.357	443.892	1.000	-1.076	1.032
	various	-2.504*	0.349	516.633	0.000	-3.533	-1.474
	no confounder	0.241	0.301	499.277	1.000	-0.647	1.130
various	timing	1.025*	0.266	395.496	0.002	0.239	1.812
	beta blockers	2.547*	0.244	408.645	0.000	1.826	3.267
	antidepressants	2.482*	0.296	394.583	0.000	1.607	3.356
	short term	2.504*	0.349	516.633	0.000	1.474	3.533
	no confounder	2.745*	0.226	444.000	0.000	2.079	3.412

		Estimates	(3 months)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		2.505	0.101	317.0	89	2.306	2.705
timing		4.287	0.174	304.1	92	3.944	4.630
beta blockers		2.680	0.137	271.3	63	2.411	2.949
antidepressants		2.816	0.222	346.0	00	2.378	3.253
short term melatonin		2.752	0.301	616.3	72	2.161	3.343
various		5.614	0.215	556.263		5.192	6.037
		Pairwise Compa	risons (3 mont	ths)			
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.781*	0.202	307.377	0.000	-2.378	-1.185
	beta blockers	-0.174	0.170	286.473	1.000	-0.678	0.329
	antidepressants	-0.310	0.244	340.794	1.000	-1.033	0.412
	short term	-0.247	0.317	573.114	1.000	-1.182	0.689
	various	-3.109*	0.238	499.100	0.000	-3.811	-2.407
timing	beta blockers	1.607*	0.221	291.090	0.000	0.951	2.262
	antidepressants	1.471*	0.283	329.231	0.000	0.635	2.307
	short term	1.535*	0.348	509.593	0.000	0.510	2.560

	various	-1.328*	0.277	432.385	0.000	-2.145	-0.510
	no confounder	1.781*	0.202	307.377	0.000	1.185	2.378
beta blockers	timing	-1.607*	0.221	291.090	0.000	-2.262	-0.951
	antidepressants	-0.136	0.261	323.037	1.000	-0.908	0.636
	short term	-0.072	0.330	528.538	1.000	-1.046	0.902
	various	-2.935*	0.255	445.386	0.000	-3.687	-2.182
	no confounder	0.174	0.170	286.473	1.000	-0.329	0.678
antidepressants	timing	-1.471*	0.283	329.231	0.000	-2.307	-0.635
	beta blockers	0.136	0.261	323.037	1.000	-0.636	0.908
	short term	0.064	0.374	497.667	1.000	-1.040	1.167
	various	-2.799 [*]	0.310	431.873	0.000	-3.712	-1.885
	no confounder	0.310	0.244	340.794	1.000	-0.412	1.033
short term	timing	-1.535*	0.348	509.593	0.000	-2.560	-0.510
	beta blockers	0.072	0.330	528.538	1.000	-0.902	1.046
	antidepressants	-0.064	0.374	497.667	1.000	-1.167	1.040
	various	-2.862*	0.370	595.206	0.000	-3.952	-1.772
	no confounder	0.247	0.317	573.114	1.000	-0.689	1.182
various	timing	1.328*	0.277	432.385	0.000	0.510	2.145
	beta blockers	2.935*	0.255	445.386	0.000	2.182	3.687
	antidepressants	2.799*	0.310	431.873	0.000	1.885	3.712
	short term	2.862*	0.370	595.206	0.000	1.772	3.952
	no confounder	3.109*	0.238	499.100	0.000	2.407	3.811

		Estimates	(4 months)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		2.197	0.103	330.1	41	1.995	2.399
timing		3.998	0.177	314.5	48	3.651	4.346
beta blockers		2.352	0.138	271.0	58	2.081	2.623
antidepressants		2.531	0.228	366.4	32	2.082	2.981
short term melatonin		2.483	0.312	678.3	46	1.871	3.096
various		5.556	0.224	609.7	20	5.116	5.997
		Pairwise Compa	risons (4 mont	ths)			ı
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	95 9 Lower Bound	% CI Upper Bound
no confounder	timing	-1.801*	0.204	318.394	0.000	-2.406	-1.197
	beta blockers	-0.155	0.172	290.370	1.000	-0.664	0.354
	antidepressants	-0.334	0.251	359.965	1.000	-1.075	0.406
	short term	-0.286	0.328	629.056	1.000	-1.254	0.681
	various	-3.359*	0.247	544.321	0.000	-4.086	-2.633
timing	beta blockers	1.646*	0.224	297.040	0.000	0.984	2.309
	antidepressants	1.467*	0.289	345.760	0.000	0.613	2.320
	short term	1.515*	0.358	555.596	0.000	0.458	2.572
	various	-1.558*	0.285	466.457	0.000	-2.400	-0.716
	no confounder	1.801*	0.204	318.394	0.000	1.197	2.406
beta blockers	timing	-1.646*	0.224	297.040	0.000	-2.309	-0.984
	antidepressants	-0.180	0.267	337.033	1.000	-0.968	0.609
	short term	-0.132	0.341	575.443	1.000	-1.137	0.874
	various	-3.205*	0.263	478.924	0.000	-3.981	-2.428
	no confounder	0.155	0.172	290.370	1.000	-0.354	0.664
antidepressants	timing	-1.467*	0.289	345.760	0.000	-2.320	-0.613
	beta blockers	0.180	0.267	337.033	1.000	-0.609	0.968
	short term	0.048	0.387	541.930	1.000	-1.092	1.188
	various	-3.025*	0.320	466.494	0.000	-3.969	-2.081

	no confounder	0.334	0.251	359.965	1.000	-0.406	1.075
short term	timing	-1.515*	0.358	555.596	0.000	-2.572	-0.458
	beta blockers	0.132	0.341	575.443	1.000	-0.874	1.137
	antidepressants	-0.048	0.387	541.930	1.000	-1.188	1.092
	various	-3.073*	0.384	654.083	0.000	-4.205	-1.941
	no confounder	0.286	0.328	629.056	1.000	-0.681	1.254
various	timing	1.558*	0.285	466.457	0.000	0.716	2.400
	beta blockers	3.205*	0.263	478.924	0.000	2.428	3.981
	antidepressants	3.025*	0.320	466.494	0.000	2.081	3.969
	short term	3.073*	0.384	654.083	0.000	1.941	4.205
	no confounder	3.359*	0.247	544.321	0.000	2.633	4.086

		Estimates	(6 months)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
no confounder		1.809	0.104	343.9	11	1.604	2.013
timing		3.593	0.179	327.5	02	3.241	3.946
beta blockers		1.933	0.139	274.2	08	1.659	2.206
antidepressants		2.158	0.235	393.7	72	1.696	2.621
short term melatonin	l .	2.214	0.322	739.5	96	1.582	2.845
various		5.485	0.232	667.000		5.029	5.941
		Pairwise Compa	risons (6 mont	ths)		'	
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
no confounder	timing	-1.785*	0.207	331.538	0.000	-2.398	-1.172
	beta blockers	-0.124	0.174	296.845	1.000	-0.638	0.390
	antidepressants	-0.350	0.257	384.985	1.000	-1.110	0.410
	short term	-0.405	0.338	684.834	1.000	-1.401	0.592
	various	-3.676*	0.255	593.025	0.000	-4.427	-2.926
timing	beta blockers	1.661*	0.227	305.975	0.000	0.990	2.332
	antidepressants	1.435*	0.296	367.525	0.000	0.561	2.309
	short term	1.380*	0.368	602.386	0.003	0.294	2.466
	various	-1.892*	0.293	504.046	0.000	-2.757	-1.026
	no confounder	1.785*	0.207	331.538	0.000	1.172	2.398
beta blockers	timing	-1.661*	0.227	305.975	0.000	-2.332	-0.990
	antidepressants	-0.226	0.273	357.043	1.000	-1.033	0.582
	short term	-0.281	0.351	623.628	1.000	-1.314	0.752
	various	-3.552*	0.271	517.039	0.000	-4.351	-2.754
	no confounder	0.124	0.174	296.845	1.000	-0.390	0.638
antidepressants	timing	-1.435*	0.296	367.525	0.000	-2.309	-0.561
	beta blockers	0.226	0.273	357.043	1.000	-0.582	1.033
	short term	-0.055	0.399	588.975	1.000	-1.230	1.120
	various	-3.327*	0.331	506.835	0.000	-4.302	-2.351
	no confounder	0.350	0.257	384.985	1.000	-0.410	1.110
short term	timing	-1.380*	0.368	602.386	0.003	-2.466	-0.294
	beta blockers	0.281	0.351	623.628	1.000	-0.752	1.314
	antidepressants	0.055	0.399	588.975	1.000	-1.120	1.230
	various	-3.272*	0.397	713.863	0.000	-4.441	-2.102
	no confounder	0.405	0.338	684.834	1.000	-0.592	1.401
various	timing	1.892*	0.293	504.046	0.000	1.026	2.757
	beta blockers	3.552*	0.271	517.039	0.000	2.754	4.351
	antidepressants	3.327*	0.331	506.835	0.000	2.351	4.302
	short term	3.272*	0.397	713.863	0.000	2.102	4.441
	no confounder	3.676*	0.255	593.025	0.000	2.926	4.427

2.4.4 Results model B (Ikelos-RS)

Table 11: Results mixed model B "Ikelos-RS" (I)

Tests of Fixed Effects								
Source	Num. df	Den. Df	F	Sig.				
Intercept	1	871.855	14.010	0.000				
GROUP	1	871.855	0.580	0.446				
ln_TIME	1	842.708	4.811	0.029				
ln_TIME* ln_TIME	1	812.591	3.315	0.069				
GROUP* ln_TIME	1	842.708	1.029	0.311				
GROUP* ln_TIME* ln_TIME	1	812.591	1.303	0.254				

	Estimates of Fixed Effects								
						95 % CI			
Parameter	Estimate	Std. Error	df	t	Sig.	Lower Bound	Upper Bound		
Intercept	3.685076	0.808585	895.680	4.557	0.000	2.098134	5.272018		
GROUP (reference: continuous intake)	GROUP (reference: continuous intake)								
GROUP (stopped after 6 months)	1.883180	2.472186	871.855	0.762	0.446	-2.968952	6.735312		
ln_TIME	-0.890177	0.505405	889.255	-1.761	0.079	-1.882103	0.101749		
ln_TIME* ln_TIME	0.075183	0.076840	875.419	0.978	0.328	-0.075630	0.225996		
GROUP* In_TIME (reference: continuous in	take)								
GROUP (stopped after 6 months) * ln_TIME	-1.532001	1.510195	842.708	-1.014	0.311	-4.496186	1.432184		
GROUP* ln_TIME* ln_TIME (reference: co	GROUP* ln_TIME* ln_TIME (reference: continuous intake)								
GROUP (stopped after 6 months) * ln_TIME* ln_TIME	0.252735	0.221406	812.591	1.142	0.254	-0.181859	0.687329		

	Estimates (6 months)									
						95 % CI				
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound			
continuous intake		2.235	0.142	756.857		1.956	2.514			
stopped after 6 months		2.092	0.432	848.544		1.244	2.940			
		Pairwise Cor	nparisons (6 m	onths)		1				
						95 9	% CI			
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound			
(1)01001	(3)GROOI	(1-3)	Sta. Elloi	uı	Sig.	Lower Bound	Opper Bound			
continuous intake	stopped after 6 months	0.143	0.455	841.156	0.753	-0.749	1.036			

		Estim	ates (1 year)				
						95 % CI	
GROUP		Mean	Std. Error	d	lf	Lower Bound	Upper Bound
continuous intake		1.899	0.082	227.832		1.737	2.061
stopped after 6 month	S	1.517	0.246	432.607		1.034	1.999
		Pairwise Co	mparisons (1	year)		ı	
						95 %	CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
continuous intake	stopped after 6 months	0.382	0.259	404.135	0.141	-0.127	0.892

	Estimates (2 years)									
						95 % CI				
GROUP	GROUP		Std. Error	df		Lower Bound	Upper Bound			
continuous intake		1.598	0.081	198.522 1.438		1.759				
stopped after 6 months		1.169	0.233	323.687		0.710	1.628			
		Pairwise Co	omparisons (2	years)						
						95 %	6 CI			
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound			
continuous intake	stopped after 6 months	0.429	0.247	305.916	0.083	-0.057	0.916			

		Estim	ates (3 years)				
						95 %	6 CI
GROUP		Mean	Mean Std. Error df		lf	Lower Bound	Upper Bound
continuous intake		1.451	0.082	203.567		1.289	1.613
stopped after 6 month	hs	1.098	0.218	317.257		0.669	1.527
		Pairwise Co	mparisons (3	years)		1	1
						95 %	6 CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
continuous intake	stopped after 6 months	0.354	0.233	299.321	0.130	-0.105	0.812

	Estim	ates (4 years)				
					95 % CI	
	Mean	Std. Error	d	lf	Lower Bound	Upper Bound
	1.360	0.085	215.435		1.192	1.528
S	1.108	0.193	277.028		0.728	1.488
	Pairwise Co	mparisons (4	years)		1	
					95 %	6 CI
(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
stopped after 6 months	0.252	0.211	265.583	0.234	-0.164	0.668
		Mean 1.360 s 1.108 Pairwise Co (J)GROUP Mean Difference (I-J)	Mean Std. Error	1.360 0.085 215	Mean Std. Error df	Mean Std. Error df Lower Bound

Table 12: Results mixed model B "Ikelos-RS" (II)

	Tests of Fixed Effects									
Source	Num. df	Den. Df	F	Sig.						
Intercept	1	792.229	4.599	0.032						
GROUP	3	834.503	2.378	0.068						
ln_TIME	1	754.756	0.458	0.499						
ln_TIME* ln_TIME	1	724.676	0.533	0.466						
GROUP* ln_TIME	3	807.127	3.681	0.012						
GROUP* ln_TIME* ln_TIME	3	782.145	3.572	0.014						

	Es	timates of Fix	xed Effects				
						95 %	i CI
Parameter	Estimate	Std. Error	df	t	Sig.	Lower Bound	Upper Bound
Intercept	3.645870	0.831837	962.319	4.383	0.000	2.013446	5.278293
GROUP (reference: continuous intake)							
GROUP (stopped after 6 months)	1.904393	2.548137	950.404	0.747	0.455	-3.096231	6.905017
GROUP (short term melatonin)	8.465769	5.918606	738.174	1.430	0.153	-3.153537	20.085075
GROUP (various)	-8.655197	4.197571	841.354	-2.062	0.040	-16.894137	-0.416258
ln_TIME	-0.858659	0.520324	962.424	-1.650	0.099	-1.879760	0.162441
ln_TIME* ln_TIME	0.069371	0.079178	955.883	0.876	0.381	-0.086012	0.224754
GROUP* ln_TIME (reference: continuous intak	e)						
GROUP (stopped after 6 months) * ln_TIME	-1.555882	1.558431	925.901	-0.998	0.318	-4.614348	1.502583
GROUP (short term melatonin) * ln_TIME	-5.696768	4.077561	709.146	-1.397	0.163	-13.702305	2.308769
GROUP (various) * ln_TIME	7.273292	2.633484	815.716	2.762	0.006	2.104089	12.442495
GROUP* ln_TIME* ln_TIME (reference: contin	nuous intake)						
GROUP (stopped after 6 months) * ln_TIME* ln_TIME	0.257683	0.228698	897.706	1.127	0.260	-0.191161	0.706527
GROUP (short term melatonin) * ln_TIME* ln_TIME	1.059169	0.663374	686.399	1.597	0.111	-0.243317	2.361656
GROUP (various) * ln_TIME* ln_TIME	-1.011053	0.398566	791.714	-2.537	0.011	-1.793425	-0.228682

		Estima	ites (6 months)					
						95 9	95 % CI		
GROUP		Mean	Std. Error		df		Upper Bound		
continuous intake		2.235	0.147	811	1.826	1.946	2.524		
stopped after 6 month	hs	2.086	0.446	923	923.373 1.211		2.960		
short term melatonin		3.620	0.657	747.059 2.331		2.331	4.909		
various	various		0.657	832.873		2.629	5.208		
		Pairwise Cor	nparisons (6 n	nonths)					
						95 9	% CI		
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound		
	stopped after 6 months	0.150	0.469	914.936	1.000	-1.091	1.391		
continuous intake	short term melatonin	-1.385	0.673	750.218	0.240	-3.164	0.395		
	various	-1.683	0.673	831.885	0.075	-3.463	0.097		
stopped after 6	short term melatonin	-1.534	0.794	810.737	0.321	-3.633	0.564		

months	various	-1.833	0.794	865.338	0.127	-3.932	0.266
	continuous intake	-0.150	0.469	914.936	1.000	-1.391	1.091
	stopped after 6 months	1.534	0.794	810.737	0.321	-0.564	3.633
short term melatonin	various	-0.299	0.929	790.927	1.000	-2.755	2.158
	continuous intake	1.385	0.673	750.218	0.240	-0.395	3.164
	stopped after 6 months	1.833	0.794	865.338	0.127	-0.266	3.932
various	short term melatonin	0.299	0.929	790.927	1.000	-2.158	2.755
	continuous intake	1.683	0.673	831.885	0.075	-0.097	3.463

		Estin	nates (1 year)					
						95 % CI		
GROUP		Mean	Std. Error		df	Lower Bound	Upper Bound	
continuous intake		1.902	0.087	233	3.462	1.732	2.073	
stopped after 6 months		1.512	0.256	457	7.929	1.008	2.016	
short term melatonin		2.726	0.453	486	5.406	1.835	3.616	
various		5.241	0.312	512	2.245	4.629	5.853	
		Pairwise Co	omparisons (1	year)		-		
						95 9	% CI	
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound	
	stopped after 6 months	0.390	0.271	425.578	0.903	-0.328	1.108	
continuous intake	short term melatonin	-0.823	0.462	473.246	0.450	-2.046	0.399	
	various	-3.338*	0.323	482.642	0.000	-4.195	-2.482	
	short term melatonin	-1.213	0.521	479.340	0.121	-2.593	0.167	
stopped after 6 months	various	-3.728*	0.404	489.582	0.000	-4.797	-2.659	
	continuous intake	-0.390	0.271	425.578	0.903	-1.108	0.328	
	stopped after 6 months	1.213	0.521	479.340	0.121	-0.167	2.593	
short term melatonin	various	-2.515*	0.550	494.557	0.000	-3.972	-1.058	
	continuous intake	0.823	0.462	473.246	0.450	-0.399	2.046	
	stopped after 6 months	3.728*	0.404	489.582	0.000	2.659	4.797	
various	short term melatonin	2.515*	0.550	494.557	0.000	1.058	3.972	
	continuous intake	3.338*	0.323	482.642	0.000	2.482	4.195	

		Estim	ates (2 years)				
						95 9	% CI
GROUP		Mean	Std. Error	df		Lower Bound	Upper Bound
continuous intake		1.600	0.086	200	5.349	1.431	1.770
stopped after 6 months		1.166	0.245	342.799		0.686	1.647
short term melatonin		2.704	0.517	546.902		1.689	3.720
various		5.882	0.305	453.081		5.283	6.481
		Pairwise Co	omparisons (2 y	years)			
		3.6 5.00				95 % CI	
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
continuous intake	stopped after 6 months	0.434	0.259	322.944	0.571	-0.254	1.122

	short term melatonin	-1.104	0.524	531.864	0.214	-2.492	0.284
	various	-4.282 [*]	0.317	425.522	0.000	-5.121	-3.443
1.0.0	short term melatonin	-1.538*	0.572	501.795	0.044	-3.052	-0.023
stopped after 6 months	various	-4.716 [*]	0.391	405.643	0.000	-5.751	-3.680
	continuous intake	-0.434	0.259	322.944	0.571	-1.122	0.254
	stopped after 6 months	1.538*	0.572	501.795	0.044	0.023	3.052
short term melatonin	various	-3.178*	0.600	521.088	0.000	-4.767	-1.589
	continuous intake	1.104	0.524	531.864	0.214	-0.284	2.492
various	stopped after 6 months	4.716 [*]	0.391	405.643	0.000	3.680	5.751
	short term melatonin	3.178*	0.600	521.088	0.000	1.589	4.767
	continuous intake	4.282*	0.317	425.522	0.000	3.443	5.121

		Estim	ates (3 years)				
						95 9	% CI
GROUP		Mean	Std. Error		df	Lower Bound	Upper Bound
continuous intake		1.450	0.087	211	1.582	1.279	1.621
stopped after 6 months		1.096	0.229	332	2.593	0.646	1.546
short term melatonin		3.154	0.437	524	1.585	2.295	4.013
various		5.875	0.277	429	9.231	5.330	6.421
		Pairwise Co	mparisons (3 y	years)		'	
						95 9	% CI
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
	stopped after 6 months	0.354	0.245	313.158	0.891	-0.295	1.004
continuous intake	short term melatonin	-1.704 [*]	0.446	505.732	0.001	-2.884	-0.523
	various	-4.425*	0.291	401.121	0.000	-5.196	-3.654
	short term melatonin	-2.058 [*]	0.493	475.023	0.000	-3.365	-0.751
stopped after 6 months	various	-4.779*	0.360	386.633	0.000	-5.733	-3.826
	continuous intake	-0.354	0.245	313.158	0.891	-1.004	0.295
	stopped after 6 months	2.058*	0.493	475.023	0.000	0.751	3.365
short term melatonin	various	-2.722*	0.518	495.227	0.000	-4.093	-1.350
	continuous intake	1.704*	0.446	505.732	0.001	0.523	2.884
	stopped after 6 months	4.779*	0.360	386.633	0.000	3.826	5.733
various	short term melatonin	2.722*	0.518	495.227	0.000	1.350	4.093
	continuous intake	4.425*	0.291	401.121	0.000	3.654	5.196

Estimates (4 years)									
					% CI				
GROUP	Mean	Std. Error	df	Lower Bound	Upper Bound				
continuous intake	1.355	0.090	225.368	1.179	1.532				
stopped after 6 months	1.107	0.203	286.007	0.707	1.506				
short term melatonin	3.688	0.446	492.331	2.812	4.564				
various	5.694	0.254	369.907	5.195	6.193				
	Pairwise	Comparisons (4 yea	rs)		I				

						95 % CI	
(I)GROUP	(J)GROUP	Mean Difference (I-J)	Std. Error	df	Sig.	Lower Bound	Upper Bound
	stopped after 6 months	0.249	0.222	274.736	1.000	-0.341	0.839
continuous intake	short term melatonin	-2,333*	0.455	476.645	0.000	-3.538	-1.128
	various	-4,339*	0.269	348.903	0.000	-5.052	-3.625
	short term melatonin	-2,582*	0.490	447.167	0.000	-3.880	-1.283
stopped after 6 months	various	-4,587*	0.325	333.916	0.000	-5.450	-3.725
	continuous intake	-0.249	0.222	274.736	1.000	-0.839	0.341
	stopped after 6 months	2,582*	0.490	447.167	0.000	1.283	3.880
short term melatonin	various	-2,006*	0.513	458.820	0.001	-3.365	-0.646
	continuous intake	2,333*	0.455	476.645	0.000	1.128	3.538
	stopped after 6 months	4,587*	0.325	333.916	0.000	3.725	5.450
various	short term melatonin	2,006*	0.513	458.820	0.001	0.646	3.365
	continuous intake	4,339*	0.269	348.903	0.000	3.625	5.052

^{*} The mean difference is significant at the 0.05 level.

References for Supplements

- Aebi C. Validierung der neuropsychologischen Testbatterie CERAD-NP: eine Multi-Center Studie. 2002. PhD Thesis. Universität Basel.
- American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien. IL: 2014.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington. VA: 2015.
- Djang DSW, Janssen MJR, Bohnen N, *et al.* SNM practice guideline for dopamine transporter imaging with ¹²³I-Ioflupane SPECT 1.0. *J Nucl Med* 2012;53:154–163.
- Goetz CG. Tilley BC. Shaftman SR. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating-scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008;23:2129–2170.
- Guy W. "Clinical Global Impressions". ECDEU Assessment Manual for Psychopharmacology Revised. Rockville. MD: U.S. Department of Health. Education and Welfare; Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs 1976;218–222.
- Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': olfactory performance assessed by the combined testing of odour identification, odor discrimination and olfactory threshold. *Chem Senses* 1997;22:39–52.
- Kunz D, Bes F. Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations. *Neuropsychobiol* 1997;36:211–214.
- Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. *Mov Disord* 1999;14:507–511
- Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. *J Sleep Res* 2010;19:591–6.
- Norman G. Likert scales, levels of measurement and the "laws" of statistics. *Advances in Health Sciences Education* 2010;15:625–32.
- Schmid NS, Ehrensperger MM, Berres M, Beck IR, Monsch AU. The extension of the German CERAD-Neuropsychological Assessment Battery with tests assessing subcortical, executive and frontal functions improves accuracy in dementia diagnosis. *Geriatr Cogn Disord Extra* 2014;4:322–334.
- Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19:1306–1312.
- Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's Disease patients. *J Nucl Med.* 2007;48:857–864.